Your Health, We Care
Release date: 2026-01-09 17:11:45 Recommended: 27
Capmatinib may make your skin more sensitive to sunlight, sunlamps, and tanning beds. If you develop new or worsening difficulty breathing while taking capmatinib, seek emergency medical help immediately.
Rare side effects of capmatinib include mental and neurological symptoms such as agitation, hostility, irritability, depression, confusion, dizziness, drowsiness, stupor, coma, and seizures.
The digestive system may experience indigestion, constipation, and pain in the stomach, side of the body, or abdomen (such pain may radiate to the back).
Cardiovascular and fluid-related reactions can manifest as rapid heartbeat, decreased urine output, and swelling of the face, ankles, or hands.
In addition, muscle twitching, sore throat, or local skin symptoms such as pain, redness, swelling, tenderness, and fever may also occur.
Capmatinib is a substrate of CYP3A4 and an inhibitor of CYP1A2, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), MATE1, and MATE2K.
1. Strong CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors will increase capmatinib exposure, which may increase the incidence and severity of capmatinib adverse reactions; close monitoring of adverse reactions is required.
2. Strong and moderate CYP3A inducers: Concomitant use should be avoided; co-administration with strong or moderate CYP3A inducers will reduce capmatinib exposure and efficacy.
3. Substrates of CYP1A2, P-gp, BCRP, MATE1 or MATE2K: Concomitant use with these substrates will increase the exposure and adverse reactions of these substrates; if co-administration is unavoidable, the dose of CYP1A2, P-gp, BCRP, MATE1 or MATE2K substrates should be reduced in accordance with the approved prescribing information.
1. Based on animal studies and its mechanism of action, administration to pregnant women may cause fetal harm.
2. There are no available data on the use of capmatinib in pregnant women.
3. Before initiating treatment, the pregnancy status of females of reproductive potential should be verified.
1. Females of reproductive potential: Use effective contraception during treatment and for 1 week after the last dose.
2. Males with female partners of reproductive potential: Use effective contraception during treatment and for 1 week after the last dose.
1. There are no available data on whether capmatinib or its metabolites are present in human or animal milk, or their effects on breastfed infants or milk production.
2. Women are advised not to breastfeed during treatment and for 1 week after the last dose.
